SORP BD FACSAria II

SORP BD FACSAria II

• 批准号: 7595159
• 负责人: Beth Deirdre Jamieson-Karavodin
• 金额: $ 50万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-01-01 至 2009-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7595159
• 关键词: 8 year old; Acquired Immunodeficiency Syndrome; Adrenal Glands; Aging; Arts; B cell differentiation; Beta Cell; Cancer Center; Carcinogens; Cell Cycle Regulation; Cell Separation; Cell Therapy; Cells; Clone Cells; Communicable Diseases; Conflict (Psychology); Core Facility; Dental; Deposition; Detection; Development; Electronics; Fees; Flow Cytometry; Fluorescence; Fluorochrome; Funding; Funding Applicant; Grant; HIV; Immunobiology; Inborn Genetic Diseases; Infection prevention; Institutes; Investigation; Laboratories; Lasers; Lymphocyte; Malignant Neoplasms; Malignant neoplasm of lung; Manufacturer Name; Marketing; Molecular; Mycobacterium tuberculosis; PTGS2 gene; Pathway interactions; Phagosomes; Productivity; Property; Protocols documentation; RNA Interference; Recovery; Regulation; Research; Research Personnel; Research Project Grants; Safety; Sampling; Schedule; Science; Screening procedure; Services; Sorting - Cell Movement; Speed; Staining method; Stains; Stem cells; Time; Vaccines; Workload; cost; design; detector; improved; instrument; interest; medical schools; meetings; microbicide; new technology; novel; novel therapeutics; pathogen; public health relevance; research study

DESCRIPTION (provided by applicant): Funding is requested for a Special Order Research Product BD FACSAria II cell sorter for the UCLA Flow Cytometry Core Facility (FCCF) established in 1988. Last year, under Director Dr. Beth Jamieson and Manager Ingrid Schmid, the FCCF provided sorting for 80 UCLA laboratories. Direct grants from the Jonsson Cancer Center and the UCLA AIDS Institute, the David Geffen School of Medicine, grants from the UCLA Chancellor's office, and user fees support the FCCF. The BD Aria II will replace a FACSVantage SE that is over 8 years old and lacks the technical capabilities required by FCCF users. These shortcomings have created scheduling conflicts for access to the single BD FACSAria currently in the FCCF. Compared to the FACSVantage, the FACSAria II will be equipped with: enhanced high-speed sorting and electronics for increased sort recoveries, higher fluorescence sensitivity, a yellow-green laser for improved detection of PE and PE- tandem fluorochromes, 10 fluorescence detectors, improved safety features for biohazardous sorts, and the Automated Cell Deposition Unit for single cell cloning. These are features UCLA investigators have indicated as critical for the progress of their research. To meet the very high demand for timely cell sorting, the FCCF has maintained three cell sorters since 2003. However, two are FACSVantage sorters which are technologically outdated and will be losing manufacturer support for service and parts. The one FACSVantage we are asking to replace through this grant was used by 41 NIH-funded investigators in the last year alone. Should the instrument break down, it would jeopardize the many research projects that depend on it for cell separation. The new BD FACSAria II will relieve the deficiencies of the current instruments in the FCCF, offer state-of-the-art sort features, accommodate the excess workload by decreasing sort times, and consequently will also lower the cost per experiment. The BD FACSAria II is requested as a shared instrument to support numerous research projects including, but not limited to, the investigation of: i) RNA interference in lymphocytes; ii) cell cycle control of beta cell mass; iii) the immunobiology of B cell differentiation; iv) COX-2 and PGE2-dependent pathways in lung cancer; v) the development of adrenal cortical cell therapy; vi) carcinogen activation and screening; vii) the M. tuberculosis phagosome; viii) and the molecular regulation of dental stem cell property. The FCCF has established novel staining protocols and standards for sorting of hazardous samples. The FCCF staff will continue to develop and adapt novel technologies for use with the new instrument to support UCLA investigators in their efforts to remain on the cutting edge of science. PUBLIC HEALTH RELEVANCE: We are requesting funding for a highly specialized instrument, a cell sorter, to replace an aging instrument that is not as sensitive, fast, or as good at recovering cells of interest to UCLA biomedical researchers as the cell sorters currently on the market. The UCLA investigators who will use this instrument are attempting to design new therapeutic strategies for inherited disorders, infectious diseases, cancer and aging as well as to develop vaccines and microbicides to prevent infection with pathogens such as HIV. The increased sensitivity of the new instrument will allow these researchers to ask more detailed questions, while the increased speed of the cell sorter will allow more investigators to use it in a single day increasing productivity and decreasing both the cost to the investigator and the time to make important discoveries.

描述（由申请人提供）：申请资金用于1988年建立的UCLA流式细胞术核心设施（FCCF）的特殊订单研究产品BD FACSAria II细胞分选仪。去年，在主任Beth Jamieson博士和经理Ingrid Schmid的领导下，FCCF为加州大学洛杉矶分校的80个实验室提供了分拣服务。来自琼森癌症中心和加州大学洛杉矶分校艾滋病研究所、大卫格芬医学院的直接赠款、加州大学洛杉矶分校校长办公室的赠款和用户费用支持FCCF。BD Aria II将取代使用超过8年且缺乏FCCF用户所需技术能力的FACSVantage SE。这些缺点导致访问目前在FCCF中的单个BD FACSAria时出现调度冲突。与FACSVantage相比，FACSAria II将配备：增强的高速分选和电子设备，用于提高分选回收率，更高的荧光灵敏度，用于改进PE和PE串联荧光染料检测的黄绿色激光器，10个荧光检测器，改进的生物危害分选安全功能，以及用于单细胞克隆的自动细胞沉积单元。这些都是加州大学洛杉矶分校的研究人员指出，他们的研究进展的关键特征。为了满足对及时细胞分选的极高需求，自2003年以来，FCCF维持了三台细胞分选机。然而，其中两台是FACSVantage分拣机，它们在技术上已经过时，将失去制造商对服务和零件的支持。我们要求通过这笔拨款更换的FACSVantage仅在去年一年就被41名NIH资助的研究人员使用。如果仪器发生故障，将危及许多依赖它进行细胞分离的研究项目。新的BD FACSAria II将缓解FCCF中现有仪器的不足，提供最先进的分拣功能，通过减少分拣时间来适应额外的工作量，从而也将降低每次实验的成本。BD FACSAria II被要求作为一种共享工具，以支持许多研究项目，包括但不限于：i）淋巴细胞中的RNA干扰; ii）β细胞群的细胞周期控制; iii）B细胞分化的免疫生物学; iv）肺癌中的考克斯-2和PGE 2依赖性通路; v）肾上腺皮质细胞疗法的开发; vi）致癌物活化和筛选; vii）M.结核吞噬体; viii）和牙齿干细胞性质的分子调控。FCCF制定了新型染色方案和危险样本分类标准。FCCF的工作人员将继续开发和调整新技术，以支持加州大学洛杉矶分校的研究人员努力保持在科学的前沿。公共卫生相关性：我们正在申请资助一种高度专业化的仪器，细胞分选机，以取代老化的仪器，这种仪器不如目前市场上的细胞分选机灵敏、快速或善于回收加州大学洛杉矶分校生物医学研究人员感兴趣的细胞。加州大学洛杉矶分校的研究人员将使用这种仪器试图设计新的治疗策略，用于遗传性疾病，传染病，癌症和衰老，以及开发疫苗和杀微生物剂，以防止感染艾滋病毒等病原体。新仪器灵敏度的提高将使这些研究人员能够提出更详细的问题，而细胞分选仪速度的提高将使更多的研究人员能够在一天内使用它，从而提高生产率，减少研究人员的成本和做出重要发现的时间。